ESMO 2018 | Selecting the right combination therapy in HCC: challenges
Cirrhosis is seen in many hepatocellular carcinoma (HCC) patients, impairing liver function. Jean Frédéric Blanc of Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, identifies this as a hurdle to selecting suitable drug combinations for patients. Speaking at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Dr Frédéric Blanc highlights the challenges associated with identifying the right treatment with a good safety and efficacy profile for the right patient, before giving his perspectice on where the field is moving.
Get great new content delivered to your inboxSign up